Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Epidemiology

Internal Medicine

Genetics

Show all topics

DOI

10.1016/s0140-6736(17)31442-3

Other Formats

PDF